Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

Share Price is delayed by 15 minutes
Get Live Data
26.40    0.20 (0.76%)
Bid:
26.10
Ask:
27.10
Spread: 1.00 (3.831%)
Market Cap: £113.65m
EKF Live PriceLast checked at - London Stock Exchange

Intraday Ekf Diagnostics Share Chart

Board Changes

27 Apr 2026 07:00

RNS Number : 9952B
EKF Diagnostics Holdings PLC
27 April 2026
 

 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Board Changes

Appointment of Chief Financial Officer

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-quoted global diagnostics business, announces the appointment of Helen Jones FCA as Chief Financial Officer ("CFO"). Helen will join the Board and assume the role of CFO with immediate effect.

 

Helen Jones is an experienced CFO with over 20 years' experience leading finance, operations, and strategic transactions in high-growth, technology-driven AIM listed businesses.

 

Helen joins EKF from Surgical Science, a leading provider of medical simulation solutions, where she has assumed a senior Group-level role following its acquisition of Intelligent Ultrasound Group plc in February 2025, with responsibility spanning post-acquisition integration and operational cost reduction, Group statutory reporting, and sustainability leadership. Prior to the acquisition, Helen spent five years as CFO of Intelligent Ultrasound Group plc, an AIM-listed company supplying simulation and AI-based ultrasound training solutions to the healthcare sector. During her tenure, Helen led two successful equity placings to fund growth and innovation, played a central role in both the £40.6 million divestment of its Clinical AI division to GE Healthcare and the subsequent sale of the Simulation business to Surgical Science.

 

Before joining Intelligent Ultrasound, Helen held a senior finance role within AIM-listed oil and exploration company Amerisur Resources plc and prior to that spent 11 years in various senior financial positions at Tata Steel Europe. Helen is a fellow of the Institute of Chartered Accountants in England and Wales having trained and qualified with PwC in 2004.

 

Helen succeeds Stephen Young, who is retiring from the Board. Steve will be available to support Helen to ensure a smooth handover but will step down from the Board with immediate effect. The Board would like to extend its sincere thanks to Steve for his financial stewardship since joining the Company in September 2023 and wishes him well in his retirement.

 

 

Commenting, Gavin Jones, Chief Executive Officer, said: "We are delighted to welcome Helen to the EKF team at a key time as we execute on our five-year development plan for accelerated growth. Helen's track record in listed healthcare technology businesses, her experience executing complex transactions, and her capital markets expertise make her an excellent fit for EKF as we accelerate our five-year plan. Her appointment reflects our commitment to building a leadership team capable of delivering our ambitious growth targets."

 

Additional Disclosures Required under the AIM Rules for Companies

The following additional information is provided with regards to the appointment of Helen Mary Kinsey Jones (aged 47) in accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies:

 

Current Directorships/partnerships

Directorships/partnerships within the last five years:

None

IML Finance Limited

Intelligent Ultrasound Innovations Limited

Intelligent Ultrasound Limited

Intelligent Ultrasound North America Inc

Inventive Medical Limited

Medaphor International Limited

Surgical Science UK Limited

Surgical Science UK Holdings Limited

 

Helen does not hold any shares or options in the Company.

 

There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

 

The person responsible for arranging the release of this Announcementon behalf of the Company is Gavin Jones, Chief Executive Officer.

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Julian Baines, Executive Chair

 via Walbrook PR

Gavin Jones, Chief Executive Officer

 

Singer Capital Markets (Nominated Adviser & Broker)

Tel: +44 (0)20 7496 3000

Phil Davies / Patrick Weaver

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Alice Woodings 

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

 

EKF is an AIM-listed global diagnostics business focussed on:

 

Point-of-Care analysers in the key areas of Hematology and Diabetes 

Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASEAESMEMSEFL
Date   Source Headline
20th May 20265:41 pmRNSLong Term Incentive Plan Award
19th May 202612:24 pmRNSResult of AGM
19th May 20267:00 amRNSAGM statement & positive Q1 trading update
27th Apr 20267:00 amRNSBoard Changes
24th Apr 20264:43 pmRNSPosting of Annual Report & Notice of AGM
13th Apr 20267:00 amRNSAcquisition of assets from Beep Insights
10th Apr 20269:12 amRNSShare Buyback
8th Apr 20262:33 pmRNSShare Buyback
7th Apr 20261:09 pmRNSShare Buyback
2nd Apr 20267:00 amRNSShare Buyback
31st Mar 20265:59 pmRNSShare Buyback
24th Mar 20267:00 amRNSFull year results
20th Mar 202611:25 amRNSShare Buyback
19th Mar 202611:20 amRNSShare Buyback
19th Mar 20267:00 amRNSHolding(s) in Company
18th Mar 20269:58 amRNSShare Buyback
6th Mar 20267:00 amRNSShare Buyback
5th Mar 20267:00 amRNSNotice of Results
3rd Mar 20267:00 amRNSThree-year Hematology purchasing agreement
2nd Mar 20263:30 pmRNSTotal Voting Rights
27th Feb 20267:00 amRNSShare Buyback
19th Feb 20267:00 amRNSShare Buyback Programme
2nd Feb 20267:00 amRNSShare Buyback & Completion of Buyback Programme
30th Jan 20267:00 amRNSShare Buyback
29th Jan 20267:00 amRNSShare Buyback
28th Jan 202611:41 amRNSShare Buyback
27th Jan 20267:00 amRNSFY 2025 Trading Update
15th Jan 20267:00 amRNSShare Buyback
14th Jan 202611:43 amRNSShare Buyback
14th Jan 20269:37 amRNSShare Buyback
12th Jan 20269:45 amRNSShare Buyback
9th Jan 20265:00 pmRNSShare Buyback
8th Jan 20269:40 amRNSShare Buyback
6th Jan 20266:03 pmRNSShare Buyback
2nd Jan 202610:23 amRNSShare Buyback
31st Dec 202510:45 amRNSShare Buyback
31st Dec 202510:45 amRNSShare Buyback
30th Dec 20257:00 amRNSShare Buyback
30th Dec 20257:00 amRNSShare Buyback
29th Dec 20257:00 amRNSShare Buyback
29th Dec 20257:00 amRNSShare Buyback
24th Dec 202510:43 amRNSShare Buyback
24th Dec 202510:43 amRNSShare Buyback
23rd Dec 20255:23 pmRNSShare Buyback
23rd Dec 20255:23 pmRNSShare Buyback
22nd Dec 202511:10 amRNSShare Buyback
22nd Dec 202511:10 amRNSShare Buyback
16th Dec 20251:57 pmRNSShare Buyback
16th Dec 20257:00 amRNSExecutive Chair share purchase
8th Dec 20257:00 amRNSCancellation of Treasury Shares & TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.